Start Date
August 24, 2020
Primary Completion Date
August 31, 2023
Study Completion Date
August 31, 2023
PET/CT with F-Fluciclovine (Axumin)
Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
Loma Linda University Cancer Center, Loma Linda
Collaborators (1)
Blue Earth Diagnostics
INDUSTRY
Loma Linda University
OTHER